Hikma Pharmaceuticals PLC · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation
15 slides from Hikma Pharmaceuticals's investor presentation
Slide 1: Hikma Quality
AIKMB Quality
Slide 2: MENA Injectables
MENA Injectables AIK. || MENA market overview | | Our MENA Injectables business today || Key growth drivers for our MENA Injectables business
Slide 3: The MENA region comprises 17 countries with a pharmaceutical market of around $12 billion
The MENA region comprises 17 countries with an estimated AIKMA pharmaceutical market size of around $12 billion* — Algeria aq — Kuwait Bahrain & Qatar va Saudi Arabia * Source: Arab Health World
Slide 4: Population sizes in MENA continue to be fast growing
Population sizes in MENA continue to be fast growing MENA market population size and growth rate in 2011 (millions) 1.7% 14% 2.1% 29% 1.0% & < Oo 2 “a e& se af ge RS & Source: World Bank Organization 3
Slide 5: Life expectancy in the MENA region has been increasing significantly
Life expectancy in the MENA region has been increasing significantly a MENA market life expectancy in 1990 and 2011 85 > 80 - 73 + 70 - mis90* 6s m2011"* 60 + ° @ oS € S S . SPS SE SF SF KC SK SF Pe s FP SK VS ie. oy & * Source: WHO World Health Statistics 2011 for 1990 data 4 ** Source: CIA, The Wo
Slide 6: Healthcare expenditure per capita in MENA is currently very low
Healthcare expenditure per capita in MENA is currently very low compared to more developed regions -_ a Health expenditure per capita in 2010 (US$ at 2010 prices) uss 9,000 8,362 8,000 7,000 6,000 5,000 4,085 3,799 4,000 3,000 2,000 1,000 526 0 Te © S P ~ ce oe e& Europe is based on the average of t
Slide 7: Our flexible business model enables us to operate successfully in different markets
Our flexible business model enables us to operate successfully in different markets AIKMIN. > Morocco 9 7 Algeria Market dominated by government tenders No requirement to register individual products in the private market Government market is for older products, particularly in anti-infectives Marke
Slide 8: MENA Injectables has been growing strongly in our key markets
MENA Injectables has been growing strongly in our key markets MENA injectables sales growth ($ million) 2009 1540/7 2010 4 =2011 11%" ~ 25%" Algeria KSA Jordan Sudan Lebanon Source: Company information * Growth rates represent the CAGR for the period from 2008 to 2011
Slide 9: The MENA injectables market is estimated to be around $2.3 billion
The MENA injectables market is estimated to be around $2.3 billion A AIKMIN. COUNTRY teaser MAIN COMPETITORS TOP INJECTABLE PRODUCTS SHARE Saudi Arabia 520 4.7% Sanofi, Prizer, MSD, Tabuk, Samixon, Prizma, Danseton, Ciprolon Julphar Algeria 310 5.3% Roche. Sanofi, Novartis Cefizox, Ciprolon, Prograt
Slide 10: Our robust pipeline of new product launches will drive growth
Our robust pipeline of new product launches will drive growth MENA Injectables product submissions 140 120 100 - Jordan KSA & other GOO. Algeria Note: Submissions data includes oncology products 135 80 8 oy 60 40 88 38 22 22 20 7 “ " 1 3 0 _ 2 Caypt m Marketed products (2012) © Injectables submitted
Slide 11: Our enhanced regulatory focus will accelerate product registrations in MENA
Our enhanced regulatory focus will accelerate product registrations in A MENA AIKMA > The challenging and fragmented regulatory environment across the 17 MENA countries can be a barrier to registering new products > Our focus is on accelerating the product registration process through: — Astrengthen
Slide 12: The MENA oncology market is estimated to be around $1.3 billion
The MENA oncology market is estimated to be around $1.3 billion A AIKMIN. MENA oncology market, by value* Others & generics Gemzar Exjade, Tasigna MabThera - ‘Avastin Herceptin Xeloda Neupogen Estimated market value: $1.3 billion* 447 Source: Company estimates Hikma marketed oncology products in MEN
Slide 13: Oncology products will be a key growth driver in MENA
Oncology products will be a key growth driver in MENA AIKMIN MENA oncology market value by country Pending oncology approvals by country Morocco Jordan 12 Lebanon ] 10 Syri Tunisia 8 Saudi Arabia’ 64 4 2 Ss other udan ecc Yemen Egypt 0+ 2 ¢ 6 o Estimated market value: $1.3 & Ss & ms a Sse iS billion
Slide 14: Excellent opportunities to build our presence in existing markets and expand in newer markets
Excellent opportunities to build our presence in existing markets and A expand in newer markets ny = Algeria 13
Slide 15: Well positioned to grow our MENA Injectables business
Well positioned to grow our MENA Injectables business OUR GLOBAL STRATE: RATEGIC PRIORITIES IN EACH REGION >» Growing global generic injectables sales - Increasing R&D — Focusing on higher value, more differentiated products — Pursuing new in- license arrangements — Product acquisitions > Increasing